RNA interference-based therapies are proving to be powerful tools for combating various diseases, including cancer. Scientists are researching the development of safe and efficient systems for the delivery of small RNA molecules, which are extremely fragile in serum, to target organs and cells in the human body. A dozen pre-clinical and clinical trials have been under way over the past few years involving biodegradable nanoparticles, lipids, chemical modification and conjugation. On the other hand, microRNAs, which control the balance of cellular biological processes, have been studied as attractive therapeutic targets in cancer treatment. In this review, we provide an overview of RNA interference-based therapeutics in clinical trials and discuss the latest technology for the systemic delivery of nucleic acid drugs. Furthermore, we focus on dysregulated microRNAs in human cancer, which have progressed in pre-clinical trials as therapeutic targets, and describe a wide range of strategies to control the expression levels of endogenous microRNAs. Further development of RNA interference technologies and progression of clinical trials will contribute to the achievement of practical applications of nucleic acid drugs.
INTRODUCTION
RNA interference (RNAi) is the process of sequencespecific, post-transcriptional gene silencing in animals and plants initiated by double-stranded RNA (dsRNA). It is the most significant recent contribution to the field of cell biology, and Fire and Mello who discovered it were awarded the Nobel Prize for Medicine in 2006 (1) . The silencing technology to suppress the expression of pathologically or physiologically important genes by using small interfering RNA (siRNA) is applicable to many kinds of research or therapeutics for human diseases caused by specific genes, which are difficult to regulate through traditional approaches. Indeed, as the initial description of RNAi in animals, the development of RNAi-based therapies has provided a powerful new arsenal against various human diseases, such as age-related macular degeneration (AMD) (2,3), respiratory syncytial virus (RSV) infection (4), neurodegenerative disorders (5) and cancers (6 -8) .
On the other hand, in recent years, microRNAs (miRNAs) have been studied as regulators of gene expression in crucial biological processes, including cell development, differentiation, apoptosis and proliferation (9, 10) . miRNAs are noncoding small RNAs ( 22 nt) which are processed from endogenously expressed transcripts and induce translational suppression and mRNA degradation in animals, plants and viruses (11, 12) . miRNAs are first transcribed as primary miRNA ( pri-miRNA) transcripts by RNA polymerase II and then processed by Drosha in the nucleus to generate 60 -100 nt precursor-miRNA (pre-miRNA) with a hairpinlike structure. After pre-miRNAs are transported to the cytoplasm by Exportin-5, they are processed into mature miRNA duplexes by Dicer assembled with transactivating response RNA-binding protein and protein activator of PKR (13, 14) . Finally, one strand of the mature miRNA duplex, a guide strand, is incorporated into the Argonaut-containing RNA-induced silencing complex, which induces either cleavage or translational repression of targeted mRNAs based on their sequences (Fig. 1) . Once the miRNAs are unbalanced or the functions are disordered, they can be involved in the initiation and development of fatal human ailments, including cancer (15) . Indeed, many reports have shown that the widespread disruption of miRNAs was correlated with the initiation and progression of human cancer and demonstrated that an injection with synthetic RNA molecules mimics tumor suppressor miRNAs or the inhibitors of oncogenic miRNA (onco-miR) can switch dozens of cancer-related signals on or off (16) . In other words, miRNAs are potential therapeutic tools for cancer treatment, representing a superior molecular target approach to the traditional low-molecular compound approach. However, for the realization of RNAi-based therapies using siRNAs, synthetic miRNAs and miRNA inhibitors, more continuous improvements will be required. For example, the technology to avoid unwanted innate immune responses, instability of nucleic acid in vivo and off-target side effects strikingly decreases the levels of potency and efficacy of RNAi effector molecules (17 -19) . Thus, the development of drug delivery systems (DDS) for RNAi therapeutic strategies that are safer, more stable and more effective is a paramount consideration.
Although clinical applications of RNAi-based therapies have not been fully realized, numerous pre-clinical studies in animal models of human disease are providing opportunities for practical use. In this review, we provide an overview of the current clinical and pre-clinical trials of RNAi therapies and discuss strategies toward a pathway of miRNA to practical applications for cancer therapy from the viewpoint of RNAi DDS.
RNAi THERAPEUTICS DEVELOPMENT PIPELINE
In the development of RNAi technology for therapeutic medication, since the first demonstration of RNAi triggered by siRNA in mammalian cells in 2001 (20, 21) , some risktaking biotechnology companies, such as Sirna Therapeutics, Silence Therapeutics and Tekmira, started to establish a platform to develop the new technology using primarily siRNA. At first, some pharmaceutical companies ascribed the RNAi to research for directed gene silencing; however, after the first exploration of in vivo gene knockdown (22) , major pharmaceutical firms, such as Medtronic, Novartis and Merck, became involved in clinical applications. Observers were surprised by the acquisition by Merck and Roche of Sirna Therapeutics for more than one billion USD. RNAi was considered an exceptional technology for the knockdown of therapeutic target genes, and scientists anticipated that it would significantly shorten the drug development timeline. However, as a consequence of the global economic turmoil that began in 2008 and the slump in development of DDS for RNAi medicine, companies such as Merck, Pfizer, Abbott Labs and Roche were forced to curtail research in these fields. In particular, the fact that Roche halted its development of RNAi technology in 2010 was a shock throughout the industry. The Roche decision resulted in a loss of confidence in the company's ability to innovate, and their withdrawal from RNAi research was followed by other companies. However, the clinical pipeline of RNAi therapies using siRNA has been gradually growing since approximately 2011 as the RNAi technology has matured.
As shown in Table 1 , there are many candidates for clinical development in 2012. In particular, there are a number of sites for topical or local administration, such as the skin, retina and airways, which permit safe and efficient delivery without unwanted side effects. For example, according to some recent animal experiments, transtympanic administration of siRNA targeting NOX3 is significantly useful for the attenuation of cisplatin ototoxicity (23) . Furthermore, Paller et al. (24) at Northwestern University showed that spherical nucleic acid nanoparticle conjugates gold cores surrounded by immobilized siRNA directed against EGFR can be topically delivered more stably into mouse and human skin without undesirable toxicity. Thus, accessibility is a key requirement for successful RNAi in vivo to be delivered tissue or cell specifically. Since around 2008, however, the development pipeline has shifted from local to systemic delivery because more advanced delivery vehicles for systemic First, primary miRNAs (pri-miRNAs) are transcribed by RNA polymerase II and are cleaved by the enzyme Drosha into 70 nucleotides as precursor-miRNAs (pre-miRNAs). Next, these pre-miRNAs are exported to the cytoplasm with Exportin-5 and are cleaved to double-strand RNAs that do not contain a loop by Dicer. These duplexes are then associated with Argonote2 (Ago2), and one strand is removed. This RNAi-induced silencing complex (RISC) containing the guide strand triggers post-transcriptional regulation of target mRNA depending on the seed sequence of miRNAs.
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DRUG DELIVERY SYSTEM FOR SYNTHETIC OLIGONUCLEOTIDE
Nucleic acid medicines, including siRNA, miRNA and anti-miRNA, work only after they penetrate hydrophobic cellular membranes. However, it is not easy for them to go through the lipid bilayer membrane without their carrier because synthetic oligonucleotides are negatively charged. In addition to this, RNAs are very easily degraded by RNase in vivo. Accordingly, assisting carriers or chemical modifications for the progression of the transmembrane transport and for the inhibition of the degradation by serum RNases are required. Historically, viral and non-viral delivery has been utilized ( Table 2 ). In a viral delivery system, it was reported that an adenovirus carried short hairpin RNA (shRNA) expression vector targeting angiotensin type 1 (AT1) delivered into the brain intracerebroventricularly (ICV) (28) and that the miR-23b expression vector and miR-23b sponge worked in inflammatory autoimmune diseases via intra-articular (IA) infection (29) . An adeno-associated virus (AAV) was also successful at carrying a miRNA cluster into the muscle and shRNA vectors targeting mutant huntingtin into the brain by topical administration (30, 31) . Furthermore, miR-34a treatment prevented lung cancer initiation and progression via transtracheal infection, and shRNA targeting superoxide dismutase 1 (SOD1) inhibited amyotrophic lateral sclerosis progression by lentiviral-mediated RNAi (32, 33) . The herpes simplex virus, which commonly causes an eruption of fluidcontaining vesicles on the mouth, lips or face, also has potential for cancer treatment and therapeutic pain relief (34, 35) . Thus, viral-mediated gene silencing is very useful for local infection, particularly at sites that make frequent administration difficult. Although viral delivery has frequently shown higher efficiency than that by non-viral systems, preliminary clinical studies have shown that it triggered strong inflammatory reactions (36) , and these delivery vectors have caused the death of several patients in the clinic (37, 38) . Thus, understanding the details of the inflammatory mechanism and developing safer viral vehicles are important tasks ahead. On the other hand, the focus has recently been on the nonviral approach because of its advantages over viral vectors, such as non-immunogenicity, low production cost and easy quality control. This approach requires an optimized delivery reagent, such as a cationic lipid, polymers, nanoparticles, carbon nanotubes and atelocollagen (Table 2) . In cancer treatment, atelocollagen or cationic liposome-or polymermediated transfection reagents have commonly been used to deliver siRNA or miRNA to cells in vitro and in vivo. In particular, a number of reports have demonstrated a significant anti-cancer effect caused by systemic delivery of siRNA with cationic liposome (39 -41) . Similarly, a cationic polymer, polyethyleneimine, was commercialized as in vivo-jetPEI TM , provided by Life Technologies, and was used to successfully deliver siRNAs to cancer cells in animals (42, 43) . In addition, atelocollagen can be obtained from type I collagen of calf dermis and has also been expected to be a useful carrier because of its low immunogenicity and efficiency (8,44 -46) . In case of miRNA therapy, a tumorsuppressive miR-16 mimic was successfully delivered by the systemic approach using atelocollagen, and it dramatically inhibited the growth of metastatic prostate cancer (47) . Furthermore, chemically functionalized carbon nanotubes also show potential for novel biological applications for the delivery of Caspase-3 siRNA into the brain by topical injection into the cerebral cortex and reduced neurodegeneration without toxic side effects (48) .
In a recent study, the focus was on highly stabilized nanoparticles, and these nanoparticles made the systemic delivery system dramatically more efficient (25,49 -52) . For example, synthetic miR-34a mimic, which was incorporated into cholesterol, and the cationic liposome N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethyl ammonium propane (DOTAP) (1:1 mol/mol) and polyethylene glycol (PEG)-conjugated CG4-targeting single-chain antibody fragment were efficiently delivered into melanoma and inhibited lung metastasis (53) . The nanocarrier 'SNALP' by Tekmira pharmaceuticals is one of the technologies with the most potential in the clinical pipeline. SNALP is a PEG-grafted monolamellar liposome that can easily avoid opsonization and subsequent recognition by the macrophages because the hydrophilic nature of PEG constructs an aqueous coating on its particle surface (54) . In the work of Judge et al., SNALP-formulated siRNAs against PLK1 and KSP displayed significant anti-tumor effects in liver tumor model mice (26) . Successful results have already been reported in the treatment of transthyretin-mediated amyloidosis, hypercholesterolemia, Ebola virus infection (49) and cancer (50) . The clinical trials have been identified as NCT00882180, NCT01158079, NCT01148953, NCT01262235 and NCT00927459 in the ClinicalTrials.gov database (http:// clinicaltrials.gov).
The effective systemic delivery of siRNA or miRNA toward target cells or tissues has been enormous challenge for RNAi therapy. Indeed, naked siRNAs are rapidly eliminated by the kidneys, and nanoparticle-formulated siRNAs have a tendency to accumulate in the liver. In particular, their suitability for cancer cells depends on the enhanced permeability and retention effect of nanoparticles. To solve these problems, combined use with orienting molecules, such as a cell-specific ligand, can increase the cell or tumor Jpn J Clin Oncol 2013;43 (6) 599 specificity and delivery efficiency (55 -57). Calando's cyclodextrinpolymer-based delivery platform (RONDEL) consists of cyclodextrin-containing polycation, and adamantine-coupled PEG-stabilized some ligands, such as transferrin (TF), and siRNA or miRNA (Fig. 2) . This siRNA 
CHEMICAL MODIFICATIONS FOR OLIGONCLEOTIDES
In addition to the nanocarriers mentioned above, others are being sought through chemical modifications. The purpose of such modifications can be permeability into the cells, specificity for specific tissues and stability against nuclease degradation ( Fig. 3 and Table 3 ). For example, as a (63) . The company is using this strategy and a polymer-based siRNA delivery platform named dynamic polyconjugate polymer in ARC-520, which is a hepatitis B clinical candidate.
In another example, nanoparticles composed of poly (lactic-co-glycolic acid) were modified with a cellpenetrating peptide, penetratin, and used for the systemic delivery of the miR-155 inhibitor in the mouse model of lymphoma (64) . On the other hand, cell-specific factors, such as aptamers (65, 66) , peptide (64, 67) , antibodies (68, 69) and agonists (56) , can enhance cell specificity in cases of systemic administration into experimental animals. For example, octaarginine-modified liposomal particles were used to suppress an endogenous gene in the liver at low concentrations of siRNA without any toxicity (67) . Usually, targeting proteins were conjugated to cationic bridges, such as polylysine or protamine, which can mediate uptake of nucleic acids, to link targeting proteins to effector oligonucleotide (68,70 -72) . In contrast, the siRNA-aptamer chimeras have also been of interest because a completely RNA-based approach may have important advantages over other methods for targeted delivery of siRNAs in terms of cost, productivity, safety and flexibility regarding chemical modification. RNA aptamers are single-stranded oligonucleotides and bind with high affinity to specific molecular targets, such as small molecules, proteins and nucleic acids, with their 3D structure (65, 66) . Here, although antibody-mediated siRNA delivery is required for the biological production of antibodies and antibody-siRNA conjugations by using a linker such as PEG, chimeric aptamer-siRNA can be synthesized as a single unit at once. However, for the utilization of chimeric aptamersiRNA, more structured RNAs capable of binding with higher affinity and specificity have been required.
Stabilization in serum has been developed for the inhibition of the nuclease activity. Indeed, the backbone linkage introduced phosphorothioate (PS) or the sugar conjugated with protecting groups such as 2 Jpn J Clin Oncol 2013;43 (6) 601 enhance the resistance against exonuclease or endonuclease activity (73, 74) (Fig. 3) . Currently, the most consequential modification is the PS inter-nucleotide linkages that have been developed in the history of anti-sense oligonucleotides and have contributed to remarkable stabilization of double-strand RNA as well as the single-strand oligonucleotide (75, 76) . However, the influence of chirality in the phosphorus atom on the stability and the activity of duplexes is not entirely understood. Therefore, further investigation of the thermodynamic features and physiological activity with regard to the assignment of the absolute configuration will be required for therapeutic applications.
As reported above, a number of chemical modifications have been produced, which have enhanced the potential of siRNA, miRNA, miRNA inhibitors and anti-sense oligonucleotides. However, it has been required that the optimization of the modifications need to be optimized, as their efficiency depends on the position and combination. In 2012, chemical modifications were optimized for single-stranded siRNAs (ss-siRNAs), and the change was an important advancement for the practical application of RNAi therapeutics. It was shown that ss-siRNA with a number of chemical modifications, such as 5 0 -phosphonate and 2 0 -MOE-modified 5 0 -terminal nucleotide, 2 0 -F and 2 0 -O-Me motifs with contiguous PS modifications and 2 0 -MOE-modified adenosine dinucleotide at the 3 0 terminus and C16 modification, brought about significant and efficient target gene silencing in vivo via the Ago2-mediated RNAi pathway (74) . Furthermore, chemically modified ss-siRNAs targeting mutant huntingtin mRNAs have been employed as a novel nucleic acid drug for therapeutic application for Huntington's disease (77) . Although single-stranded RNAs (ssRNAs) have been shown to have extremely rapid degradation in serum and poor activities so far (78, 79) , they have advantages, such as the absence of risk of undesirable offtarget effects by passenger strand and the potential of systemic delivery without complex lipid formulations that sometimes trigger the inflammatory toxicities (80) . Hence, these stabilized ssRNAs are expected to place RNAi therapy in a prominent class of nucleic acid drugs.
DYSREGULATED MIRNA AS THERAPEUTIC TARGET IN CANCER TREATMENT
The alterations of miRNA expression profiling are significantly related with cancer initiation and progression. To identify dysregulated miRNAs in the physiological and pathological pathway of cancer malignancy is the first step for therapeutic applications. Generally, the widespread disruption of miRNAs is caused by at least three different mechanisms: the loss, amplification or mutation of a fragile cancer-related genomic region; the change of epigenetic control; and the abnormality of miRNA-processing steps. The genetic change has the potential to affect radically the abundance of miRNA, and it was reported that .50% of miRNAs locate on the fragile genomic region in cancer (81 -83) . For instance, a significant downregulation of miR-15 and miR-16, which is caused by deletion or mutation in chromosome 13q14.3, was observed in 70% of patients with chronic lymphocytic leukemia.
On the other hand, CpG-island hypermethylation and histone modification as good markers for functional miRNA have also been investigated by using 5-aza-2 0 -deoxycytidine and a histone decetylase inhibitor, such as 4-phenylbutyric acid or trichostatin A (84 -86) . For example, miR-124a that regulates the expression of cyclin D kinase 6 was located in three chromosome loci, 8p23.1, 8q12.3 and 20q13.33, and these regions were hypermethylated in 75% of patients with primary colorectal tumors (87) . In addition to genetic and epigenetic validation, alterations of the protein machinery related to the biogenesis of miRNA might impair global (89) . According to one estimate, the widespread downregulation of the miRNA expression levels is prevalent in several cancer types (90, 91) . In contrast, a kind of multi-functional polyphenolic compound, resveratrol, which is present in red wine, induced widespread upregulation of miRNAs and inhibited tumor growth through the acceleration of the expression and activity of Ago2 (92) . Thus, the observation and management of the total balance of miRNAs are important for cancer diagnosis and treatment.
INHIBITION OF MIRNA EXPRESSION AND FUNCTIONS
For the therapeutic applications of miRNA, the intracellular expression levels of miRNAs have to be artificially controlled. Although it is relatively easy to upregulate miRNAs, the strategy for the downregulation of miRNAs requires a refined miRNA inhibitor such as a chemically modified antisense oligonucleotide. As the inhibitor against endogenous miRNA, locked nucleic acid (LNA), which has a methylene bridge connecting 2 0 and 4 0 carbons, is one of the most widely used platforms. LNA nucleotide organizes the phosphate backbone in the N-type (C3 0 -endo) conformation, whereas, in general, the conformations of DNA or RNA duplexes are flexible between N-type and S-type (C2 0 -endo). This conformational change contributes to a more efficient stacking of the nucleobases and functional inhibition of target miRNAs (93) . In therapeutic applications, LNA against the liver-expressed miR-122, which is a potential therapeutic target in the hepatitis C virus (HCV), accomplished the long-lasting reduction of mature miR-122 and suppression of HCV viremia (94, 95) . Furthermore, LNA against hypoxia inducible factor 1a, the primary transcription factor activated by hypoxia that allows glycolysis and angiogenesis to progress, provides significant lowering of the expression of HIF1-a and suppression of tumor growth. Clinical trials of these LNA against miR-122 (SPC3649) and HIF1-a (EZN-2968) have progressed to Phases I and II by Santaris Pharma.
In addition to this, as competitive inhibitors of miRNAs, the miRNA sponge (96), the tough decoy (TuD) RNA (97), antagomirs (98) , peptide nucleic acids (PNAs) (99) and anti-miRNA oligonucleotides (AMOs) (100) have also been developed toward medical practice targeting onco-miRNA as well as LNA. Antagomirs composed of 2 0 -O-Me, PS and cholesterol modification were the first miRNA inhibitors that provided a significant reduction in mammals (98, 101) . However, antagomirs were excluded as clinical candidates because they were less effective than other miRNA inhibitors. PNAs are replaced its sugar-phosphate backbone to N-(2-aminoethyl)glycine units, also have a potential to inhibit miRNA activities. Reports indicate that PNA-DNA chimeras have the potential to inhibit miRNA in vitro and in vivo (99) . On the other hand, unlike chemically modified ASOs, a miRNA decoy can be stably integrated into the chromosomes and degrade miRNA targets. The stable suppression of miR-301a by a miRNA decoy was reported to have inhibited tumor growth by the upregulation of NF-kB-repressing factor in pancreatic cancer (102) , and TuD-RNA against miR-122a showed a significant suppression of the HCV replication in liver hepatocytes (103) .
PIPELINE OF MIRNA IN CANCER TREATMENT
In a recent study, onco-miRs or tumor-suppressive miRs that work as master regulators in cellular processes have been identified, and a number of pre-clinical trials have been conducted by firms such as MiRagen Therapeutics, Regulus Therapeutics, Santaris Pharma and Mirna Therapeutics (Table 4) . For example, miR-34a, which is one of the beststudied tumor-suppressive miRNAs, was a therapeutic target in solid tumor treatment by Mirna Therapeutics and Regulus Therapeutics. miR-34a is commonly downregulated in human cancer, such as prostate, breast, lung, kidney, bladder, ovary and skin cancer (104 -106) , and was identified as a target of the tumor suppressor gene p53. The reduction of miR-34a by CpG methylation is observed in multiple types of cancer. The restoration of miR-34s has the potential to cause cell cycle arrest, senescence and apoptosis (107) . Mirna Therapeutics has also been conducting pre-clinical trials with miR-16 and let-7 mimics, which are potent tumorsuppressive miRNAs (47, 108, 109) . Furthermore, pre-clinical trials of miRNA inhibitors against miR-21 and miR-10b, which are targeted as onco-miRs in hepatocellular carcinoma and glioblastoma, are being conducted. In addition to these developments, a number of non-public candidates for miRNA therapy are being considered by Mirna Therapeutics; they include miR-Rx01, 02, 03, 06 and 07. Thus, miRNA therapeutics using miRNA mimics or inhibitors has been growing in pre-clinical studies and might appear in clinical trials over the next several years.
CONCLUSION
RNAi is one of the most versatile knockdown tools in recent biotechnology, and the potential of RNAi therapeutics using miRNA for cancer treatment has been rapidly expanding. In particular, unlike siRNAs as a tool that specifically impairs the function of a target gene, miRNAs work as key regulators that control target genes and establish balanced cellular organization. Indeed, the disruption of such a balance leads to the possibility of a tumor to become malignant (110, 111) .
To utilize these discoveries of cellular biological basic research for clinical investigation, further innovations in the field of the delivery systemic and chemical modifying strategies are desired. Indeed, although chemically modified ASOs and ss-siRNAs are potentially promising nucleic acid drugs that can efficiently manage RNAi in animals, immeasurable synthesis costs and technical difficulties for bulk production remain. In addition, safer and more effective delivery systems, including a viral approach, are needed. However, the progression of RNAi technology over the past decade has been remarkable, and the hope is that ongoing investigations will result in the use of RNAi therapeutics as a prominent cancer treatment.
